AstraZeneca PLC (AZN) vs GSK plc (GSK)
GSK leads on 9 of 16 compared metrics.
A side-by-side comparison of AstraZeneca PLC and GSK plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 20, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
AZN
AstraZeneca PLC
$164.52HealthcareDelayed quote: Jul 20, 2026, 4:00 PM EDT
GSK
GSK plc
$50.04HealthcareDelayed quote: Jul 20, 2026, 4:00 PM EDT
Total return — AZN vs GSK
growth of $100 · dividends reinvested · last 30yAZN +1949.5%GSK +575.7%AZN compounded faster
AZN GSK
AZN vs GSK: by the numbers
- •AZN is the larger company ($127.48B vs $100.22B market cap).
- •GSK trades at the lower earnings multiple (11.45 vs 12.39 P/E).
- •GSK converts more revenue to profit (17.76% vs 17.19% net margin).
- •AZN grew revenue faster over the past five years (16.99% vs 0.63% CAGR).
- •GSK pays the higher dividend yield (3.47% vs 1.95%).
Which is better, AZN or GSK?
Metric tally: AZN 7 · GSK 9It depends on what you're optimizing for:
ValueGSK(lower P/E)
GrowthAZN(faster 5Y revenue CAGR)
IncomeGSK(higher dividend yield)
QualityGSK(higher ROIC)
Metrics side by side
Valuation
| Metric | AZN | GSK |
|---|---|---|
| P/E ratio | 12.39 | 11.45● |
| Forward P/E | 16.07 | 14.46● |
| P/S ratio | 2.12● | 2.39 |
| P/B ratio | 2.71● | 3.39 |
| PEG ratio | 0.29 | 0.02● |
| EV / EBITDA | 7.69● | 8.52 |
| FCF yield | 6.29% | 7.98%● |
Profitability
| Metric | AZN | GSK |
|---|---|---|
| Gross margin | 81.68%● | 72.67% |
| Operating margin | 23.69% | 25.65%● |
| Net margin | 17.19% | 17.76%● |
| ROE | 21.95% | 25.19%● |
| ROIC | 13.03% | 16.61%● |
Dividends
| Metric | AZN | GSK |
|---|---|---|
| Dividend yield | 1.95% | 3.47%● |
| Payout ratio | 24.24% | 23.66% |
Growth (annualized)
| Metric | AZN | GSK |
|---|---|---|
| Revenue CAGR (5Y) | 16.99%● | 0.63% |
| EPS CAGR (5Y) | 22.02%● | 14.05% |
| FCF CAGR (5Y) | 15.68%● | -0.35% |
| Total return CAGR (5Y) | 9.53% | 9.66% |
Frequently asked
- Which is better, AZN or GSK?
- It depends on your goal. value: GSK (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: GSK (higher dividend yield); quality: GSK (higher ROIC). Across all compared metrics, GSK leads 9 to 7.
- Is AZN or GSK cheaper?
- On trailing earnings, GSK is cheaper: AZN trades at a 12.39 P/E and GSK at 11.45.
- Which has grown faster, AZN or GSK?
- Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus GSK at 0.63%.
- Does AZN or GSK pay a bigger dividend?
- AZN yields 1.95% and GSK yields 3.47% based on trailing dividends and the latest price.
- Is AZN or GSK more profitable?
- GSK runs the higher net margin — AZN at 17.19% versus GSK at 17.76%.
- Which has been the better investment, AZN or GSK?
- Over the past 10-year, AZN delivered the higher annualized total return — AZN at 13.66% versus GSK at 6.23%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AstraZeneca P/E ratioGSK P/E ratioAstraZeneca dividend yieldGSK dividend yieldAstraZeneca ROEGSK ROEAstraZeneca operating marginGSK operating marginAstraZeneca revenue growthGSK revenue growthAstraZeneca free cash flowGSK free cash flow
AstraZeneca & GSK appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 20, 2026.